top of page

Top pharma companies by revenues in 2023|Big Pharma Profits |Top 20 pharma companies | iPharmaCenter

Updated: Nov 2


Merck revenues exclude animal health revenues

Telegram Channel (iPharmaCenter)



Johnson and Johnson reported Q1 revenues for 2023.

The company reported revenues of $24.7 billion, an increase of 5.6% versus 2022 ($23.4 billion).

The consumer health revenues were $3.8 billion, pharmaceutical revenues were $13.4 billion, and MedTech revenues were $7.5 billion.

Also read: Top pharmaceutical companies of 2022

The best-selling products are Stelara ($2.4 billion), Darzalex ($2.2 billion), Imbruvica ($0.83 billion), and Tremfya ($0.64 billion).


Johnson & Johnson has released its financial results for the second quarter of 2023. During this period, the company reported a sales growth of 6.3% to reach $25.5 billion.

In the pharmaceutical segment, worldwide adjusted operational sales experienced a growth of 3.9%. However, when excluding the COVID-19 vaccine from the equation, the adjusted operational sales grew by a more substantial 6.2%. The growth in this area was driven by the success of key drugs such as Darzalex, contributing $2.4 billion in revenue; Stelara, with $2.8 billion; and Tremfya, with $706 million.

Also read: ESMO 2023 Updates

In the first half of 2023, Johnson & Johnson's total revenues reached $50.3 billion.

Among their best-selling drugs were Darzalex, bringing in $4.7 billion in revenue, and Imbruvica, contributing $1.7 billion.


During the third quarter of 2023, Johnson and Johnson reported a 6.8% increase in reported sales, amounting to $21.4 billion.

The revenues from the first nine months were $63.8 billion.

Specifically, within the Innovative Medicine segment, the company achieved a commendable 4.4% growth in adjusted operational sales on a global scale. Excluding the contribution from the COVID-19 Vaccine, operational sales witnessed a surge of 8.2%.

Best selling products (until Q3 2023)


$ 8.1 billion


$ 7.2 billion

Invega product

$ 3.0 billion


$ 2.5 billion


$ 2.2 billion



Roche reported a drop in revenues by 3% at CER. However, the pharmaceutical division saw an increase in revenues by 9%, while there was a drop of 28% in the diagnostics division.

Also read: HAS assessment outcomes

The pharmaceutical division revenues were $13.2 billion. The best-selling products were Ocrevus ($1.8 billion), Perjeta ($1.2 billion), Hemlibra ($1.2 billion), Tecentriq ($1.0 billion), and Actemra ($0.8 billion).


Roche presented Q3 financial results, reporting total revenues of CHF 14.3 billion. The cumulative revenues in the first nine months amounted to CHF 44 billion ($ 48.9 billion).

The company consistently grew in group sales, with a 1% increase at constant exchange rates (CER) throughout the first nine months. This growth gained substantial momentum in the third quarter, with a remarkable 7% surge.

Within the Pharmaceuticals Division, sales saw a notable upswing of 9%, primarily attributed to the sustained high demand for newer medications. Meanwhile, the Diagnostics Division experienced a 7% increase in its base business, albeit the overall divisional sales registered an 18% decrease.

Also read: United European Gastroenterology (UEGW) Week 2023

In the third quarter, Roche's top-performing pharmaceuticals included Ocrevus, which generated CHF 1.6 billion; Hemlibra with CHF 1.0 billion, Perjeta at CHF 913 million; and Actemra, which brought in CHF 647 million in revenue.

Ocrevus emerged as Roche's best-selling product, capturing a remarkable 24% share of the global multiple sclerosis market and accumulating revenues of CHF 4.8 billion during the first nine months of 2023.



Pfizer reported a 29% drop in revenues for the first quarter. Comirnaty revenues dropped by 75%, resulting in $3.0 billion, while Paxlovid revenues reached $4.0 billion. Other best-selling drugs included Eliquis ($1.9 billion), the Prevnar family ($1.6 billion), and Ibrance ($1.1 billion).

Also read: ECTRIMS-ACTRIMS meeting | MSMilan 2023


Pfizer's financial performance in the second quarter of 2023 has been reported, reflecting revenues of $12.7 billion. The primary factor contributing to this quarter's 53% operational decrease in revenue was the anticipated decline in Paxlovid and Comirnaty revenues.

Consequently, the company has revised its revenue guidance for the full year 2023 to $67 to $70 billion, adjusting its expectations for non-COVID operational revenue growth to fall between 6% and 8%.

In the initial half of 2023, Pfizer's total revenues amounted to $31 billion. The significant revenue drivers during this period included Comirnaty with $4.5 billion, Paxlovid with $4.2 billion, Eliquis contributing $3.6 billion, the Prevnar family of products generating $3.0 billion, and Ibrance with $2.4 billion in revenue.

Also read: World Conference on Lung Cancer (WCLC23) | 2023


In its third-quarter report, Pfizer announced revenues totaling $12.9 billion, signifying a notable 42% decrease compared to the same period in 2022. This decline is primarily attributed to decreased revenues from Comirnaty and Paxlovid.

Over the initial nine months of the year, Pfizer's reported revenues amounted to $44.2 billion, marking a 42% reduction compared to the previous year's figures.



Novartis reported revenues of $13.0 billion in the first quarter of 2023, with a growth of 8% at constant currency. The innovative medicines revenues increased by 7%, and Sandoz division revenues increased by 8%.

The company's best-selling products were Entresto ($1.4 billion) and Cosentyx ($1.1 billion).


Novartis reported revenues of $13.6 billion in the second quarter of 2023; in the first six months, the company reported revenues of $26.6 billion. In the second quarter, Novartis saw a 9% growth in sales (at constant currencies) or 7% in USD terms. The core operating income also rose by 17% at constant currencies or 9% in USD terms.

The best-selling drugs of H1 2023 are Entresto ($2.9 billion), Cosentyx ($2.3 billion), Promacta/Revolade ($1.1 billion), and Tafinlar + Mekinist ($0.95 billion).

Also read: American Society of Retina Specialists (ASRS) | 2023



Merck's pharmaceutical segment experienced a decrease of 10%, with first-quarter revenues at $12.7 billion due to the reduced demand for Lagevrio. However, Keytruda revenues grew at an impressive 20%, generating $5.8 billion in revenue. Other growth drivers for Merck were Gardasil/Gardasil 9 at $2.0 billion and Januvia at $0.88 billion.

Also read: Drug approvals in 2023


In the third quarter of 2023, the pharmaceutical department reported revenues of $14.2 billion. Over the first nine months of the year, the total revenue reached $40.4 billion. Notably, the company's top-selling products for this period were Keytruda, generating $18.4 billion in revenue, followed by Gardasil/Gardasil 9 at $7.0 billion, and Januvia, which contributed $1.6 billion to the company's earnings.

Best selling drugs of Merck


Revenues in billions


$ 18.4 billion

Gardasil / Gardasil 9

$ 7.0 billion



AbbVie reported revenues of $12.2 billion in the first quarter of 2023, down nearly 10%, primarily due to a significant drop in Humira's revenues. Immunology revenues fell by 9%, with Humira revenues at $3.5 billion, a 25% drop compared to the first quarter of 2022. US revenues dropped by 26%. Skyrizi and Imbruvica were the other growth drivers for AbbVie, with revenues of $1.3 billion and $0.88 billion, respectively.

Also read: Top CMS Pharmaceutical Expenditures: Analyzing High-Expenditure Medications


AbbVie has released its financial results for the second quarter of 2023, showing net revenues of $13.9 billion, a decline of 4.9% on a reported basis and 4.2% on an operational basis. The global net revenues from the immunology portfolio in the second quarter were $6.8 billion, a decrease of 5.5% on a reported basis or 5.0% on an operational basis. Specifically, Humira's global net revenues amounted to $4.0 billion, Skyrizi's net revenues were $1.9 billion, and Rinvoq's net revenues reached $918 million.

In the first six months of 2023, AbbVie achieved total revenues of $26 billion, with significant contributions coming from Humira ($7.5 billion), Skyrizi ($3.2 billion), Imbruvica ($1.8 billion), and Rinvoq ($1.6 billion).

Also read: Best selling drugs | 2023


AbbVie's third-quarter report for 2023 has revealed a total revenue of $13.9 billion, marking a 6% decrease compared to the previous year. This decline in revenue can be primarily attributed to a significant drop in Humira sales, which saw a 36% decrease compared to the third quarter of 2022. Despite this setback, AbbVie had positive developments in its product portfolio, with Skyrizi generating $2.1 billion in revenue, and Rinvoq generating $1.1 billion, both reflecting an impressive increase of more than 50%.

Cumulatively, the first nine months of the year yielded revenues of $40.0 billion. AbbVie's best-selling products during this period included Humira, generating $11.0 billion in revenue, followed by Skyrizi at $5.4 billion, Imbruvica at $2.7 billion, and Rinvoq at $2.7 billion.



Sanofi's first quarter revenues were $11.3 billion, primarily driven by Dupixent at $2.5 billion.


Sanofi reported revenues of $11 billion in the second quarter of 2023.

Specialty Care experienced notable growth of 11.8%, primarily attributed to Dupixent, with revenues amounting to $2.8 billion, representing an increase of 34.2%.

Vaccines also performed well, achieving a growth of 9.1%. This growth was driven by robust sales of PPH vaccines in the Rest of the World and the supply of COVID vaccines in Europe.

In the first half of 2023, Sanofi's net revenues reached $22.2 billion, and the key driver behind this success was Dupixent, generating $5.4 billion in revenue. The company has expressed confidence in Dupixent, expecting it to generate revenues of $10 billion in 2023.

Also read: How common is depression?


In the third quarter of 2023, Sanofi disclosed its Q3 revenues, reporting total sales of $12.6 billion. Notably, Dupixent played a significant role in these figures, contributing $3.0 billion in revenue during the third quarter.

When examining the company's performance over the first nine months of the year, Sanofi accumulated revenues totaling $34.0 billion.

8. BMS


Bristol-Myers Squibb (BMS) reported revenues of $11.3 billion, a 3% decrease. However, US revenues increased by 4%, driven primarily by Eliquis and Opdivo. The primary revenue drivers for BMS were Eliquis at $3.4 billion, Opdivo at $2.2 billion, and Revlimid at $1.7 billion.

Also read: NICE Assessment Outcomes


Bristol Myers Squibb reported second-quarter revenues of $11.2 billion, which experienced a 6% decline. However, when adjusted for foreign exchange, the fall was 5%. This decrease was primarily attributed to lower sales of Revlimid. On the positive side, the decline was partially offset by steady sales from in-line products and the contribution of their new product portfolio.

In the international markets, revenues declined by 8% to reach $3.3 billion during the quarter. After adjusting for foreign exchange impacts, the decline was 6%. This decrease was primarily driven by the erosion of Revlimid and Eliquis due to generic competition and lower average net selling prices.

During the first six months, BMS announced total revenues of $22.56 billion. The primary contributors to this revenue were Eliquis, generating $6.6 billion, followed by Opdivo, with $4.3 billion. Additionally, Pomalyst and Orencia contributed reported revenues of $1.7 billion. Revlimid, the company's blockbuster, reported revenues of $3.2 billion during this period, a drop of 39%.



AstraZeneca's revenues for the first quarter of 2023 were $10.9 billion. Oncology revenues increased by 16%, with Tagrisso generating $1.4 billion, Imfinzi generating $0.9 billion, and Lynparza generating $0.65 billion. Biopharmaceutical revenue increased by 15%, with Farxiga generating $1.3 billion. The revenues from Soliris were $0.83 billion, and Ultomiris at $0.65 billion.

10. GSK


GSK reported revenues of $8.7 billion in the first quarter of 2023, with an increase of 15% in vaccine revenues and 9% in general medicines, whereas specialty pharmacy revenues dropped by 33%.

The revenues from Shingrix were $1.0 billion, and dolutegravir products were $1.6 billion.

Also read: CHMP Positive Opinions

bottom of page